Drug Trial Radar · NCT00256750
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
Last checked: Nov 20, 2026Latest source record: Aug 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
738
Actual
Start
Mar 2005
Primary completion
Jun 2008
Study completion Apr 2015
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn if Belatacept can provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and patient survival as well as drug safety will also be studied.
Conditions
- Kidney Transplantation
- Chronic Kidney Failure
Interventions
Cyclosporine (CsA)Drug
tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
Belatacept LI (less intensive)Drug
solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
Belatacept MI (more intensive)Drug
solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants Surviving With a Functioning Graft by Month 12Time frame: Day 1 to Month 12
- Percent of Participants With a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12 or With a Decrease in mGFR Greater Than or Equal to 10 mL/Min/1.73m^2 From Month 3 to Month 12Time frame: Month 12; Month 3 to Month 12
- Percent of Participants Experiencing Acute Rejection (AR) Post-transplant by Month 12Time frame: Day 1 to Month 12
Locations
105 sites in 21 countries. Site status is shown where the registry gives one.
University Of Alabama At Birmingham
Birmingham, Alabama
Loma Linda University Medical Center-Transplantation Institu
Loma Linda, California
Cedars Sinai Medical Center
Los Angeles, California
California Institute Of Renal Research
San Diego, California
University Of California San Francisco Medical Center
San Francisco, California
University Of Colorado Health Sciences Center
Aurora, Colorado
Yale University School Of Medicine-Yale New Haven Hospital
New Haven, Connecticut
Piedmont Hospital
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
Medical College Of Georgia
Augusta, Georgia
University Of Chicago Hospitals
Chicago, Illinois
University Of Iowa Hospitals And Clinics
Iowa City, Indiana
University Of Kentucky
Lexington, Kentucky
Maine Tranplant Program
Portland, Maine
Western New England Renal & Transplant Associates, Pc
Springfield, Massachusetts
Henry Ford Hospital, Transplant Institute
Detriot, Michigan
University Of Minnesota
Minneapolis, Minnesota
Washington University School Of Medicine
St Louis, Missouri
Recanati/Miller Transplantation Institute
New York, New York
Columbia University College Of Physicians & Surgeons
New York, New York
University Of Rochester Medical Center
Rochester, New York
University Of North Carolina At Chapel Hill
Chapel Hill, North Carolina
Carolinas Medical Center
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Div Of Multi-Organ Trans, Hepato-Biliary-Pancreatic Surgery
Philadelphia, Pennsylvania
Musc
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor University Medical Center
Dallas, Texas
Fletcher Allen Health Care
Burlington, Vermont
Inova Transplant Center
Fairfax, Virginia
Swedish Medical Center
Seattle, Washington
Sacred Heart Medical Ctr Providence Medical Research Ctr
Spokane, Washington
University Of Wisconsin
Madison, Wisconsin
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
La Plata, Buenos Aires, Argentina
Local Institution
Cordoba, Crd, Córdoba Province, Argentina
Local Institution
Rosario, Santa Fe Province, Argentina
Local Institution
Santa Fe, Santa Fe Province, Argentina
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.